Latest CEL-SCI Corporation Stories
NEW YORK, March 27, 2014 /PRNewswire/ -- Across the globe, there are over 13 million new cancer cases each year.
Editor Note: For more information about this release, please scroll to bottom. LONDON, March 10, 2014 /PRNewswire/ -- On Friday, March 07, 2014, the US markets
NEW YORK, Jan. 27, 2014 /PRNewswire/ -- CEL-SCI Corporation (NYSE: CVM) is engaged in the research and development of drugs and vaccines.
VIENNA, Va., March 10 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE Amex: CVM) announced today that it has received a $125,000 payment from Byron Biopharma ("Byron") under its licensing agreement where CEL-SCI granted Byron an exclusive license to market and distribute the Company's cancer drug MultikineÂ® in the Republic of South Africa (the "Territory").
VIENNA, Va., Feb. 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation (NYSE AMEX: CVM) and their scientific collaborators announced today that the Company's CEL-2000 vaccine demonstrated that it is able to block the progression of rheumatoid arthritis (RA) in a mouse model.
VIENNA, Va., Feb. 17 /PRNewswire-FirstCall/ -- The following letter is being released by CEL-SCI Corporation (NYSE AMEX: CVM) to its shareholders: Dear Fellow Shareholders: We are pleased to report to you that the past 12 months have put CEL-SCI in the best position ever.
- totally perplexed and mixed up.